Recent Updates
Recently added Catalysts
LGVN Positive Sentiment Score: 70/100

Longeveron to Present at the Planet MicroCap Showcase

Thursday, April 25, 2024 2 min read
Key Takeaway: Longeveron Inc. (NASDAQ: LGVN) has announced its participation in the Planet MicroCap Showcase scheduled for May 1-2, 2024. During the event, the company will present its advancements in regenerative medicines, specifically its lead investigational product, Lomecel-B™, a therapy derived from young adult donors' bone marrow. This conference offers Longeveron an opportunity to enhance investor relations and discuss its pipeline for conditions like hypoplastic left heart syndrome and Alzheimer’s disease. Interested investors can schedule 1x1 meetings at the conference venue in Las Vegas, NV.

Market Sentiment Analysis

POSITIVE FACTORS

  • Longeveron to present at a major investment showcase, enhancing visibility.
  • The company is developing innovative regenerative medicines.
  • Potential applications of Lomecel-B™ could address significant unmet medical needs.

Full Press Release Details

MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024.
Details for the Company’s presentation:
Date: Wednesday, May 1, 2024
Time: 4:30 p.m. PT
Webcast: Click Here
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
If you would like to book 1x1 investor meetings with Longeveron Inc. and to attend the Planet MicroCap Showcase: VEGAS 2024, please register here: https://planetmicrocapshowcase.com/signup.
1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

Tags

regenerative medicine

Frequently Asked Questions

When is Longeveron's presentation at the Planet MicroCap Showcase?

Longeveron's presentation is on May 1, 2024, at 4:30 p.m. PT.

How can I access the webcast of Longeveron's presentation?

The webcast will be available through the 'Events & Presentations' section on their website.

Where will the Planet MicroCap Showcase take place?

The event will be held at the Paris Hotel & Casino in Las Vegas, NV.

What is Lomecel-B™ developed by Longeveron?

Lomecel-B™ is an allogeneic MSC therapy aimed at various medical conditions.

What medical conditions is Longeveron targeting?

Longeveron is focusing on hypoplastic left heart syndrome, Alzheimer’s, and frailty.

Tags: LGVN Viatris Investor Conferences Healthcare Longeveron regenerative medicine Planet MicroCap Showcase Lomecel-B
Last updated: Apr 25, 2024